Medpace Holdings Inc vs Royal Caribbean Cruises Ltd — how do they compare? Medpace Holdings Inc trades at $532.42 (market cap $15.08B), while Royal Caribbean Cruises Ltd trades at $287.38 (market cap $76.75B). The key difference: Royal Caribbean Cruises Ltd is far larger — about 5.1× Medpace Holdings Inc's market cap, and Royal Caribbean Cruises Ltd pays a 1.75% dividend while Medpace Holdings Inc pays none. Which is the better fit depends on your goals.
| MEDP | RCL | |
|---|---|---|
Market Cap | $15.08B | $76.75B |
Sector | Technology | Consumer Cyclical |
52-Week High | $620.59 | $365.84 |
52-Week Low | $308.88 | $246.71 |
Enterprise Value | $14.55B | $98.03B |
Dividend Yield | — | 1.75% |
Signals from Pluang's Aura AI — not financial advice
MEDP trades at $527.93, down 1.82% today, with a bullish technical outlook supported by moving averages. The company demonstrates strong profitability with 17.19% net margins and 77.25% ROE, though valuation ratios appear elevated with a P/E of 33.83. Recent earnings have consistently beaten expectations, and cash flow is projected to improve significantly in 2026. However, the stock faces headwinds from ongoing class action lawsuits and mixed analyst sentiment with 73.69% hold ratings.
MEDP presents a mixed investment case with strong fundamental performance offset by legal overhangs and premium valuation. The company's consistent earnings beats and projected cash flow improvement support upside potential, but investors should weigh the legal risks and cautious analyst stance against the robust operational metrics.
Royal Caribbean (RCL) trades at $285.59, down 0.48% on the day, with technical indicators showing a neutral to bullish bias as the stock tests support near $285. Fundamentally, the company demonstrates strong profitability with 24.36% net margins and 50.41% ROE, supported by robust revenue growth from $8.8B in 2022 to $17.93B in 2025. Recent earnings have mostly beaten expectations, with Q1 2026 EPS of $3.60 surpassing estimates of $3.24.
The investment outlook remains positive given analyst consensus price target of $328 (15% upside), strong cash flow generation, and continued recovery in cruise demand. Key risks include high debt levels ($18.47B long-term debt), sensitivity to economic cycles, and competitive pressures in the cruise industry. The upcoming Q2 2026 earnings report on July 28 will be critical for near-term direction.
Trailing returns across standard periods
Latest headlines on both assets
Medpace Holdings, Inc. is a full-service clinical contract research organization (CRO) that provides comprehensive and scientifically-driven clinical development services to the biotechnology, pharmaceutical, and medical device industries. The company specializes in conducting global clinical trials for new drug and medical device approvals. Medpace's model emphasizes therapeutic expertise and a highly integrated approach to accelerate the clinical development process for its clients.
Read more on MEDP →Royal Caribbean is the world's second-largest cruise company, operating 64 ships across five global and partner brands in the cruise vacation industry, with 10 more ships on order. Brands the company operates include Royal Caribbean International, Celebrity Cruises, and Silversea. The company also has a 50% investment in a joint venture that operates TUI Cruises and Hapag-Lloyd Cruises, allowing it to compete on the basis of innovation, quality of ships and service, variety of itineraries, choice of destinations, and price. The company completed the divestiture of its Azamara brand in the first quarter of 2021.
Read more on RCL →